ArticleBMC cancer2026

Metronomic (mCHT) vs standard (sCHT) chemotherapy as first-line treatment in HR+/HER2- Metastatic Breast Cancer (MBC) patients following failure of endocrine treatments. The matched control VICTOR-15 study.

Marina Elena Cazzaniga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.